What are ASCO/OH(CCO) recommendations for treating stage IV non–small cell lung cancer (NSCLC) in patients with ALK alterations?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

First-line therapy:

  •  Alectinib or brigatinib should be offered.
  • If alectinib and brigatinib are not available, ceritinib or crizotinib should be offered.

Second-line therapy

  • If alectinib or brigatinib was given in the first-line setting, lorlatinib may be offered.
  • If crizotinib was given in the first-line setting, then alectinib, brigatinib, or ceritinib should be offered.

Third-line therapy

  • If crizotinib was given in the first-line setting and alectinib, brigatinib, or ceritinib in the second-line setting, then lorlatinib may be offered, or standard treatment for NSCLC without driver mutations may be offered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!